233 related articles for article (PubMed ID: 19759844)
1. Discovery and validation of urinary biomarkers for prostate cancer.
Theodorescu D; Schiffer E; Bauer HW; Douwes F; Eichhorn F; Polley R; Schmidt T; Schöfer W; Zürbig P; Good DM; Coon JJ; Mischak H
Proteomics Clin Appl; 2008 Mar; 2(4):556-570. PubMed ID: 19759844
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
4. Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer.
Alijaj N; Pavlovic B; Martel P; Rakauskas A; Cesson V; Saba K; Hermanns T; Oechslin P; Veit M; Provenzano M; Rüschoff JH; Brada MD; Rupp NJ; Poyet C; Derré L; Valerio M; Banzola I; Eberli D
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267445
[TBL] [Abstract][Full Text] [Related]
5. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
[TBL] [Abstract][Full Text] [Related]
6. The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer.
Abdollah F; Dalela D; Haffner MC; Culig Z; Schalken J
Eur Urol Focus; 2015 Sep; 1(2):99-108. PubMed ID: 28723439
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
[TBL] [Abstract][Full Text] [Related]
8. A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy.
Zhang W; Ren SC; Shi XL; Liu YW; Zhu YS; Jing TL; Wang FB; Chen R; Xu CL; Wang HQ; Wang HF; Wang Y; Liu B; Li YM; Fang ZY; Guo F; Lu X; Shen D; Gao X; Hou JG; Sun YH
Prostate; 2015 May; 75(6):653-61. PubMed ID: 25597901
[TBL] [Abstract][Full Text] [Related]
9. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
10. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
11. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.
Johnson H; Guo J; Zhang X; Zhang H; Simoulis A; Wu AHB; Xia T; Li F; Tan W; Johnson A; Dizeyi N; Abrahamsson PA; Kenner L; Feng X; Zou C; Xiao K; Persson JL; Chen L
BMC Med; 2020 Dec; 18(1):376. PubMed ID: 33256740
[TBL] [Abstract][Full Text] [Related]
14. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
15. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.
Rigau M; Ortega I; Mir MC; Ballesteros C; Garcia M; Llauradó M; Colás E; Pedrola N; Montes M; Sequeiros T; Ertekin T; Majem B; Planas J; Ruiz A; Abal M; Sánchez A; Morote J; Reventós J; Doll A
Prostate; 2011 Dec; 71(16):1736-45. PubMed ID: 21520154
[TBL] [Abstract][Full Text] [Related]
16. Predicting Prostate Biopsy Results Using a Panel of Plasma and Urine Biomarkers Combined in a Scoring System.
Albitar M; Ma W; Lund L; Albitar F; Diep K; Fritsche HA; Shore N
J Cancer; 2016; 7(3):297-303. PubMed ID: 26918043
[TBL] [Abstract][Full Text] [Related]
17. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
[TBL] [Abstract][Full Text] [Related]
18. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results.
Reissigl A; Horninger W; Fink K; Klocker H; Bartsch G
Cancer; 1997 Nov; 80(9):1818-29. PubMed ID: 9351555
[TBL] [Abstract][Full Text] [Related]
19. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
20. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
